Niranjan Sathianathen (@NiranjanJS) profile picture

Urological Surgeon.

Melbourne, Victoria
Joined March 2009
Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)Photo by Niranjan Sathianathen (@NiranjanJS)
Niranjan Sathianathen retweeted
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨 @CACancerJournal 📋 Average risk: PSA every 2 yrs, ages 50-69 📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69 📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69 🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy 🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs ⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69 🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010 🔗 doi.org/10.3322/caac.70112 @UroOnc @urotoday @UrologyTimes @PCF_Science @AmerUrological
5
112
5
200
18,234
Niranjan Sathianathen retweeted
Beyond surgery in high-risk prostate cancer. PROTEUS: adding apalutamide + hormone therapy around surgery improved 3-year freedom from recurrence: 63% vs 41%. PROTEUS/STAMPEDE/ENZARAD: Same drug class, three different answers. Maybe the question is not ‘does it work’ but ‘for whom’. @EUplatinum @Albert0Briganti @amerseburger @Uroweb @OncoAlert @myESMO #ESMO26 @APCCC_Lugano @OpenMedicineHQ
2
20
2
78
4,431
Niranjan Sathianathen retweeted
Great to finally see the results of the #PROTEUS substudy comparing #perioperative Apa+ADT with the true SOC (RP w/o neoadjuvant treatment) - which should at least reduce some concerns related to the active comparator with ADT in the main study that didn’t reflect what we actually do as a standard in HR patients #ESMO26 Outcomes in all #endpoints significant improved ✅EFS: HR 0.38, 95% CI 0.26–0.55 ✅MFS: HR 0.49, 95% CI 0.26–0.90 ✅TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43 The question remains which of these outcomes are most clinically relevant and meaningful #PROTEUS #ProstateCancer #UrologicOncology #Apalutamide #RadicalProstatectomy @oncodaily @OncoDailyGU @urotoday @Albert0Briganti @JNJInnovMed
13
27
1,334
Niranjan Sathianathen retweeted
🚨 New in @JUrology: "Language as a powerful influencer in #ProstateCancer" 🚨 ✒️ New essay w/ @uroegg & Jessica Rett @LinguisticsUcla 📄 Words are neither neutral nor fixed ♋️We use prostate cancer, a disease spanning indolent to lethal under one name, as a case study: 👉 MRI "lesion" 👉 clinically "significant" disease 👉 "positive" margin ❓ We all know these terms shape how patients hear us 🧵 5 strategies you can use today 👇
1
15
1
38
4,300
Niranjan Sathianathen retweeted
An 8 year labor of love to get this study complete but it's finally here-- a comprehensive longitudinal assessment of >250,000 @VeteransHealth patients with de novo #microhematuria, details on their cystoscopy evals, and risk factors for MH-related bladder cancer diagnoses.
3
8
1
72
5,568
Niranjan Sathianathen retweeted
Cochrane on HoLEP: 52 RCTs, 6,242 men, no external funding, search to April 2026. Vs TURP at 12 months: similar symptoms, QoL, major AEs, retreatment, erectile function. One clear win: transfusions, RR 0.19. I do HoLEP. I accept this. Thread. #MISTAudit #BPH #Urology
5
10
43
6,504
Niranjan Sathianathen retweeted
🚨 Half of focal therapy for #ProstateCancer in the US is happening where no guideline supports it 🚨 @JAMA_current research letter 👥 1,179,384 pts w/ nonmetastatic PCa, NCDB 2010 to 2023 📊 15,672 (1.3%) got focal therapy ⚠️ 51% was in low, high, or very high risk disease. -No guideline supports routine use in ANY risk group outside trials or registries ⚠️ Low risk held flat (1.8% to 2.2%) and favorable intermediate is rising (2.1% to 2.9%) while marketing and&reimbursement expand ⚠️ Focal therapy more likely w/ age ≥75 (adjusted probability 22.9%), community centers (7.6% vs 2.5% academic), nonprivate insurance ✒️From the accompanying editorial "Volume of this kind shows diffusion, not benefit." 🎯 Key points 1⃣In low risk this converts surveillance candidates into procedure pts 2⃣In high risk it is undertreatment. 3⃣Repeated use is building "an aura of legitimacy the data have not earned." We owe pts trials, not marketing. 🔗 Study: doi.org/10.1001/jama.2026.12… 🔗 Editorial: doi.org/10.1001/jama.2026.16… @QDTrinh @DrSpratticus @AmerUrological @UroOnc @SUO_YUO @urotoday @UrologyTimes @PCF_Science @PCFnews
7
33
4
63
28,862
Niranjan Sathianathen retweeted
We have completed our first Robotic Retroperitoneal Lymph Node Dissection @Austin_Health. Patients potentially only need to stay overnight. Again we are thankful to have the Da Vinci Xi robotic system. Thank you Prof. Lawrentschuk’s proctoring and Prof. Damien Bolton’s support.
2
7
2
34
3,528
Niranjan Sathianathen retweeted
🚨Neurosafe RCT(n=407) at gamechanger sess by Greg Shaw #EAU25. In men with good baseline erections having RALP, 12 mth erectile function better with neurosafe technique vs SOC (IIEF 12.7vs9.7, p<0.001) & early continence better. Published @TheLancetOncol thelancet.com/journals/lanon…
5
25
1
62
6,071
Niranjan Sathianathen retweeted
Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wi…
8
92
4
165
25,086
Out now: Penile cancer care in the Netherlands: increased incidence, centralisation, and improved survival in @BJUIjournal by Manon Vreeburg and Oscar Brouwer #publicationoftheweek ⬇️ bit.ly/49FdYz4
2
4
1
12
4,502
Niranjan Sathianathen retweeted
1/4 Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial - ScienceDirect. sciencedirect.com/science/ar…
13
54
6
148
46,105
Niranjan Sathianathen retweeted
Remembering Christchurch | a GU Cast Special. We put together this one hour video podcast to remember the devastating 2011 Christchurch Earthquake and explain why it matters to @USANZUrology @gu_onc Some amazing stories in there youtu.be/qenpYNofAQ8 – at Melbourne, Victoria
2
6
1
29
7,970
Niranjan Sathianathen retweeted
STOPCAP meta-analysis: Docetaxel addition to ADT ➡️ limited OS/PFS benefit in low-volume metachronous mCSPC ➡️ best suited for high volume/potentially bulky/T4 primary tumors @ChrisSweens1 @BertrandTOMBAL @pgd81 @mattsydes @Prof_Nick_James sciencedirect.com/science/ar… #ProstateCancer
1
73
3
151
35,773
Niranjan Sathianathen retweeted
Cost-effectiveness of systemic treatment intensification in men with metastatic hormone-sensitive #ProstateCancer. Presented by @NiranjanJS @USANZUrology. #AUA23 written coverage by @rksayyid @UofT > https://nitter.cf/t.co/Y7wnWSMuSS @AmerUrological
5
7
1,602
Niranjan Sathianathen retweeted
Diagnostic Accuracy of PSMA PET/CT for Initial Staging of Intermediate to High-risk Prostate Cancer: Systematic Review and Meta-analysis "PSMA-PET should be used as a first-line approach for the initial staging of PCa." sciencedirect.com/science/ar… @EUplatinum @declangmurphy
1
60
3
175
16,323
Niranjan Sathianathen retweeted
🎯After 21 yrs in Rotterdam PCa screening study: Invite 246, diagnose 14 to prevent 1 death. Invite 121, diagnose 7 to prevent 1 metastatic case. Overdiagnosis now strongly reduced (risk stratification, MRI etc). Let's bring this advantage to all men who may benefit! @uroweb
3
61
3
130
25,251
Niranjan Sathianathen retweeted
Replying to @JonathanSOBrien
@JonathanSOBrien & @declangmurphy deliver one of highest quality videos of #EAU23 with slick, professional production values. This is how all videos should be put together! If only rest of our community had skills of this group. Key message: RP is safe/feasible after #Lutectomy
2
6
31
2,310
Cutting edge presentation on the use of ICG during robotic ILND @JonathanSOBrien @lawrentschuk @gu_onc. Super slick AV @declangmurphy #EAU23 – at Milan, Lombardy
2
16
1,072